Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.47 | — | — | — | 0.49 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.96 | 245.52 | 174.60 | 13.24 | 0.33 | 13.21 | 13.73 | 10.72 | 23.20 | 76.95 | 51.68 | 25.15 | 32.34 |
| — | +1758.9% | +1171.5% | +23.5% | -98.6% | -82.8% | -73.4% | -57.4% | -28.3% | +147.5% | +39.6% | -33.0% | -61.5% | |
| P/B Ratio | 1.51 | 2.09 | 0.96 | 1.10 | 0.91 | 2.03 | 1.52 | 1.82 | 2.54 | 3.59 | 2.07 | 2.21 | 2.32 |
| — | +2.9% | -36.6% | -39.6% | -64.2% | -43.6% | -26.4% | -17.3% | +9.4% | -10.6% | -61.4% | -75.5% | -83.6% | |
| P/FCF | 12.58 | — | — | — | 0.47 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.09 | — | — | — | 0.10 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 2.90 | — | — | — | 0.10 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CureVac N.V.'s operating margin was -4959.5% in Q2 2025, up 1168.9 pp QoQ and down 4449.5 pp YoY. The trailing four-quarter average of -2829.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 57.3% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.2% | -77.8% | 2.0% | 89.7% | 95.6% | -182.1% | -236.9% | -171.8% | -47.3% | -241.1% | -189.5% | -584.4% | -114.8% |
| — | +57.3% | +100.9% | +152.2% | +302.0% | +24.5% | -25.1% | +70.6% | +58.8% | -115.6% | -259.1% | -736.7% | +60.7% | |
| Operating Margin | 33.2% | -4959.5% | -6128.4% | -302.4% | 74.6% | -510.0% | -592.6% | -411.1% | -327.8% | -947.4% | -846.6% | -1039.5% | -467.2% |
| — | -872.5% | -934.2% | +26.4% | +122.8% | +46.2% | +30.0% | +60.4% | +29.8% | -216.5% | -1251.5% | -7676.2% | +4.2% | |
| Net Margin | 30.3% | -4783.9% | -5832.5% | -226.4% | 68.4% | -502.5% | -570.2% | -384.0% | -295.3% | -889.5% | -805.4% | -1101.8% | -424.3% |
| — | -852.0% | -922.9% | +41.0% | +123.2% | +43.5% | +29.2% | +65.1% | +30.4% | -211.2% | -1200.6% | -23360.5% | +13.6% |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.7% | -9.7% | -7.8% | -4.6% | 61.4% | -17.6% | -14.6% | -15.1% | -7.8% | -9.9% | -9.2% | -22.2% | -7.6% |
| — | +45.2% | +47.0% | +69.4% | +889.0% | -78.0% | -58.9% | +32.2% | -2.1% | -11.5% | -316.0% | -7847.8% | +59.5% | |
| ROA | 20.4% | -8.3% | -6.7% | -4.0% | 47.9% | -11.6% | -9.5% | -10.4% | -5.6% | -7.2% | -6.3% | -14.5% | -5.2% |
| — | +28.4% | +29.3% | +61.8% | +957.3% | -61.6% | -52.3% | +28.8% | -7.9% | -22.0% | -353.2% | -10500.4% | +37.7% | |
| ROIC | 65.0% | -19.5% | -16.4% | -14.0% | 129.4% | -27.6% | -32.0% | -40.3% | -24.4% | -37.3% | -41.8% | -88.9% | -36.5% |
| — | +29.4% | +48.6% | +65.2% | +629.8% | +26.1% | +23.5% | +54.7% | +33.1% | +39.3% | -109.2% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 169.9% YoY to 6.17x, strengthening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 | 0.06 | 0.08 | 0.07 |
| — | -40.7% | -36.4% | -30.9% | -20.8% | +66.2% | +57.7% | +2.5% | +5.9% | -3.3% | -4.3% | +88.1% | -18.8% | |
| Debt / EBITDA | 0.20 | — | — | — | 0.11 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.28 | 6.17 | 7.65 | 7.28 | 6.20 | 2.29 | 2.25 | 2.57 | 3.56 | 3.86 | 7.61 | 3.74 | 3.61 |
| — | +169.9% | +240.1% | +183.5% | +73.9% | -40.7% | -70.4% | -31.3% | -1.3% | +11.8% | +129.2% | +42.3% | +102.1% | |
| Quick Ratio | 7.27 | 6.16 | 7.64 | 7.27 | 6.19 | 2.28 | 2.25 | 2.43 | 3.41 | 3.72 | 7.33 | 3.58 | 3.56 |
| — | +170.0% | +239.7% | +198.7% | +81.7% | -38.6% | -69.3% | -32.1% | -4.4% | +9.8% | +128.6% | +45.1% | +121.0% | |
| Interest Coverage | — | -109.28 | -164.35 | — | 2612.62 | -474.97 | -215.64 | — | -13.23 | -40.27 | -63.46 | -14.99 | -96.64 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCureVac N.V.'s current P/E is 6.5x. The average P/E over the last 1 quarters is 0.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CureVac N.V.'s current operating margin is 33.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CureVac N.V.'s business trajectory between earnings reports.